Clinical Trial Detail

NCT ID NCT02258451
Title Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Bayer
Indications

Her2-receptor negative breast cancer

Therapies

Exemestane + Everolimus

radium Ra 223 dichloride

Age Groups: adult

Additional content available in CKB BOOST